Gene therapy expression vectors based on the clotting Factor IX promoter

Area of Science:

• Gene Therapy
• Molecular Biology
• Hepatology

Background:

• The liver is a key target for gene therapy, particularly for correcting clotting factor gene defects.
• Optimizing gene expression is crucial for effective liver-directed gene therapies.

Purpose of the Study:

• To design and evaluate optimized expression vectors for liver-directed gene therapy using the Factor IX gene promoter.
• To enhance the activity and persistence of gene expression in liver cells.

Main Methods:

• Engineered the Factor IX gene promoter by adding a multimerized upstream regulatory element.
• Assayed promoter activity in the human liver cell line Hep G2.
• Compared the optimized promoter's activity against the SV40 enhancer/early promoter and assessed tissue specificity.

Main Results:

• The optimized Factor IX promoter demonstrated at least a 20-fold increase in activity compared to the proximal promoter alone in Hep G2 cells.
• The engineered promoter showed significantly higher activity and short-term expression persistence than the SV40 enhancer/early promoter.
• Inclusion of an apolipoprotein E/C locus control region did not further enhance expression; vectors exhibited high tissue specificity.

Conclusions:

• The optimized Factor IX promoter represents a significant advancement for liver-directed gene therapy vectors.
• This enhanced promoter provides robust and persistent gene expression with high tissue specificity, suitable for treating genetic liver disorders.